Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Nitric oxide and symptom reduction in schizophrenia.

Coyle JT.

JAMA Psychiatry. 2013 Jul;70(7):664-5. doi: 10.1001/jamapsychiatry.2013.210. No abstract available.

PMID:
23699799
2.

Sodium nitroprusside treatment of clozapine-refractory schizophrenia.

Maia-de-Oliveira JP, Belmonte-de-Abreu P, Bressan RA, Cachoeira C, Baker GB, Dursun SM, Hallak JE.

J Clin Psychopharmacol. 2014 Dec;34(6):761-3. doi: 10.1097/JCP.0000000000000217. No abstract available.

PMID:
25203464
3.

[Nitroprusside treatment of schizophrenic patients].

Haroche A.

Soins Psychiatr. 2013 Jul-Aug;(287):6. French. No abstract available.

PMID:
23951732
4.

Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial.

Hallak JE, Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, Belmonte-de-Abreu P, Baker GB, Dursun SM.

JAMA Psychiatry. 2013 Jul;70(7):668-76. doi: 10.1001/jamapsychiatry.2013.1292.

PMID:
23699763
5.

The effects of sodium nitroprusside treatment on cognitive deficits in schizophrenia: a pilot study.

Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, Belmonte-de-Abreu P, Baker GB, Dursun SM, Hallak JE.

J Clin Psychopharmacol. 2015 Feb;35(1):83-5. doi: 10.1097/JCP.0000000000000258. No abstract available.

PMID:
25502490
6.

Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis.

Crippa JA, Hallak JE, Abílio VC, de Lacerda AL, Zuardi AW.

CNS Neurol Disord Drug Targets. 2015;14(8):970-8. Review.

PMID:
26350340
7.

Sodium nitroprusside, a nitric oxide donor for novel treatment of schizophrenia, may also modulate dopaminergic systems.

Maia-de-Oliveira JP, Lobão-Soares B, Baker GB, Dursun SM, Hallak JE.

Schizophr Res. 2014 Nov;159(2-3):558-9. doi: 10.1016/j.schres.2014.08.020. Epub 2014 Sep 13. No abstract available.

PMID:
25223842
8.

Schizophrenia and antipsychotic medication--better adherence, better outcomes?

Staring AB, Van der Gaag M, Mulder CL.

Schizophr Res. 2013 Dec;151(1-3):296-7. doi: 10.1016/j.schres.2013.10.035. Epub 2013 Nov 14. No abstract available.

PMID:
24238966
9.

Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.

Purdon SE.

J Psychiatry Neurosci. 2000 Mar;25(2):108-16. Review. No abstract available.

10.

Comparing symptom response among antipsychotic medications in CATIE.

Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH.

J Clin Psychopharmacol. 2013 Feb;33(1):123-6. doi: 10.1097/01.jcp.0000426178.43831.ed. No abstract available.

PMID:
23288232
11.

Novel antipsychotics and the neuropsychological deficiencies of schizophrenia.

Hawkins KA.

J Psychiatry Neurosci. 2000 Mar;25(2):105-7. No abstract available.

12.

Recent advances in treatments for schizophrenia.

Kane JM.

J Clin Psychiatry. 2011;72 Suppl 1:3. doi: 10.4088/JCP.10075su1.00. No abstract available.

13.

The Psychiatric Symptom Assessment Scale (PSAS).

Bigelow LB, Berthot BD.

Psychopharmacol Bull. 1989;25(2):168-73. No abstract available.

PMID:
2574891
14.

Strategies for enhancing drug therapy of schizophrenia.

Schooler NR, Levine J.

Am J Psychother. 1983 Oct;37(4):521-32. Review.

PMID:
6140869
15.

[Treatment of schizophrenia with "atypical antipsychotic drugs". Quality of life as a measure of treatment success].

[No authors listed]

Krankenpfl J. 2002;40(7-9):230-1. German. No abstract available.

PMID:
12514869
16.

The course and treatment of schizophrenia in later life.

Ruskin PE, Nyman G.

Hosp Community Psychiatry. 1988 Sep;39(9):929-30. Review. No abstract available.

PMID:
2905692
17.

Does atypical antipsychotic medication improve executive function in schizophrenia?

Collie A, Maruff P, Snyder PJ.

Int J Neuropsychopharmacol. 2006 Oct;9(5):629-30; author reply 631-2. Epub 2006 Aug 8. No abstract available.

PMID:
16893492
18.

Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia.

Taneli F, Pirildar S, Akdeniz F, Uyanik BS, Ari Z.

Arch Med Res. 2004 Sep-Oct;35(5):401-5.

PMID:
15610909
19.

Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes.

Himelhoch S, Taylor SF, Goldman RS, Tandon R.

Biol Psychiatry. 1996 Feb 1;39(3):227-9. No abstract available.

PMID:
8837987
20.

Understanding schizophrenia: the impact of novel antipsychotics.

Remington G.

Can J Psychiatry. 1995 Sep;40(7 Suppl 2):S29-32. Review. No abstract available.

PMID:
8564914

Supplemental Content

Support Center